<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>16</volume><submitter>Roccati E</submitter><pubmed_abstract>&lt;h4>Introduction&lt;/h4>Modifiable risk factors account for a substantial proportion of Alzheimer's disease (AD) cases and we currently have a discrete AT(N) biomarker profile for AD biomarkers: amyloid (A), p-tau (T), and neurodegeneration (N). Here, we investigated how modifiable risk factors relate to the three hallmark AT(N) biomarkers of AD.&lt;h4>Methods&lt;/h4>Participants from the European Prevention of Alzheimer's Dementia (EPAD) study underwent clinical assessments, brain magnetic resonance imaging, and cerebrospinal fluid collection and analysis. Generalized additive models (GAMs) with penalized regression splines were modeled in the AD Workbench on the NTKApp.&lt;h4>Results&lt;/h4>A total of 1,434 participants were included (56% women, 39% &lt;i>APOE&lt;/i> ε4+) with an average age of 65.5 (± 7.2) </pubmed_abstract><journal>Frontiers in aging neuroscience</journal><pagination>1346214</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10879413</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Modifiable dementia risk factors and AT(N) biomarkers: findings from the EPAD cohort.</pubmed_title><pmcid>PMC10879413</pmcid><pubmed_authors>King AE</pubmed_authors><pubmed_authors>Eastgate J</pubmed_authors><pubmed_authors>Collins JM</pubmed_authors><pubmed_authors>Carboni M</pubmed_authors><pubmed_authors>EPAD Consortium</pubmed_authors><pubmed_authors>Bindoff AD</pubmed_authors><pubmed_authors>Logan C</pubmed_authors><pubmed_authors>Alty J</pubmed_authors><pubmed_authors>Roccati E</pubmed_authors><pubmed_authors>Borchard J</pubmed_authors><pubmed_authors>Vickers JC</pubmed_authors></additional><is_claimable>false</is_claimable><name>Modifiable dementia risk factors and AT(N) biomarkers: findings from the EPAD cohort.</name><description>&lt;h4>Introduction&lt;/h4>Modifiable risk factors account for a substantial proportion of Alzheimer's disease (AD) cases and we currently have a discrete AT(N) biomarker profile for AD biomarkers: amyloid (A), p-tau (T), and neurodegeneration (N). Here, we investigated how modifiable risk factors relate to the three hallmark AT(N) biomarkers of AD.&lt;h4>Methods&lt;/h4>Participants from the European Prevention of Alzheimer's Dementia (EPAD) study underwent clinical assessments, brain magnetic resonance imaging, and cerebrospinal fluid collection and analysis. Generalized additive models (GAMs) with penalized regression splines were modeled in the AD Workbench on the NTKApp.&lt;h4>Results&lt;/h4>A total of 1,434 participants were included (56% women, 39% &lt;i>APOE&lt;/i> ε4+) with an average age of 65.5 (± 7.2) </description><dates><release>2024-01-01T00:00:00Z</release><publication>2024</publication><modification>2026-07-14T18:23:42.074Z</modification><creation>2025-04-05T00:31:16.224Z</creation></dates><accession>S-EPMC10879413</accession><cross_references><pubmed>38384935</pubmed><doi>10.3389/fnagi.2024.1346214</doi></cross_references></HashMap>